OptimizeRx (OPRX) has seen a significant boost in its stock value, rocketing by more than 22% in extended trading on Thursday. This impressive leap follows the release of the company's robust second-quarter financial outcomes, which not only surpassed market forecasts but also demonstrated substantial growth across key financial indicators. The strong performance underscores a positive trajectory, instilling considerable investor confidence in the digital health firm's future prospects.
\nThe Michigan-based digital health innovator's stock closed at $12.84 in regular trading before ascending to $15.75 per share in the after-hours session. This notable increase was fueled by a stellar earnings report for the second quarter. OptimizeRx exceeded expectations with a profit margin of $0.22 per share and a reported revenue of $29.2 million, significantly higher than the projected $22.6 million.
\nStephen L. Silvestro, the chief executive of OptimizeRx, highlighted the company's continuous profitable expansion, noting that year-to-date contracted revenue had grown by over 30% compared to the previous year. This substantial increase positions the company for a powerful conclusion to the second half of the fiscal year.
\nDelving deeper into the financial specifics, OptimizeRx recorded a 55% year-over-year increase in revenue, reaching $29.2 million for the second quarter. Gross profit also experienced a remarkable surge, climbing 59% year-over-year to $18.6 million. Furthermore, the company achieved a Generally Accepted Accounting Principles (GAAP) net income of $1.5 million for the quarter, a significant turnaround from the $4.0 million GAAP net loss reported during the same period last year.
\nIn response to these outstanding results, OptimizeRx has adjusted its full-year 2025 financial guidance upwards. The company now anticipates revenue to fall within the range of $104 million to $108 million, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) expected to be between $14.5 million and $17.5 million. This revised outlook indicates strong confidence from the management in their sustained growth and operational efficiency.
\nThe company's shares are now trading at elevated levels, signaling robust investor belief in its ongoing expansion and financial stability. The positive momentum, supported by favorable market trends, suggests a bright outlook for OptimizeRx as it continues to innovate within the digital healthcare landscape.